New Cancer Therapies-Juniper Publishers

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology



New Cancer Therapies

Authored by Daniela Vazquez Capdepon

Malignant neoplasms are the second cause of death in Argentina, according to official data from the Argentine Ministry of Health, 25% of annual deaths are due to cancer, although it has detected a reduction of approximately 10% mortality rate cancer over the last 15 years. This condition causes between 55 and 60,000 deaths annually in Argentina. Values between 1% and 2.5% of the adult population, with a strong increase as the population ages. The new systemic cancer therapies are the result of decades of investment in research and clinical. The two-way interaction between the clinic and the lab opened a whole new outlook, with a growing universe of “new molecular targets” possible to be manipulated pharmacologically. The mechanisms of regulation of cell signaling, generation of neovasculature (angiogenesis), cell cycle control, among others, were more openly exposed on the molecular level. The elite of drugs that access approval (monoclonal antibodies, drugs modulating the intracellular signaling) exhibits new benefits and in turn, raises uncertainty about their potential long-term results in the search for her within the available therapies. This article is limited to the analysis of drugs used in so-called “adult solid tumors.” One of the practical results of the enormous impetus given to research in Molecular Biology and Human Genetics is the development of a broad category of new drugs, called “new molecular targets therapies” or “targeted therapies”


Comments

Post a Comment

Popular posts from this blog

Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing

Image
Cancer Therapy & Oncology- Juniper Publishers                                                      Abbreviations cfDNA: Cell-Free DNA; NGS: Next-Generation Sequencing; WGS: Whole Genome Sequencing; WES: Whole Exome Sequencing; GH: Guardant Health; CT: Circulogene Theranostics Editorial Targeted therapy specifically aims at tumor genetic alterations s the hallmark of precision medicine. Companion diagnostic testing utilized to determine the presence or absence of certain oncogenic mutations prior to targeted treatment under the current medical guidelines will enable improved clinical outcome, and thus serves as a vital component for precision medicine. Standard clinical practice to assess genetic mutations in cancer patients has historically been through direct sampling of tumor tissue with biopsy or surgical resection. Unfortunately, tissue biopsy is one-time single-site sampling, painful, costly, and can miss the dynamics of tumor clonally evolution during disease progression. The
Read more

Recent Advance in Diagnosis, Pathogenesis and Risk Stratification of Essential Thrombocythemia

Image
Cancer Therapy & Oncology- Juniper Publishers                                               Abstract In the 2016 version of WHO classification, bone marrow morphology is critical in the distinction between ET and pre-PMF. Reticulin-fiber grading becomes central: grade 1 or less is needed for ET. Furthermore,  CALR  assessment must be performed in all ET patients without  JAK2  mutation. Some prognostic implications have been described for  CALR  mutations, i.e., a lower risk of thrombosis in ET. Abbreviations:  MPN: Myelo Proliferative Neoplasm; WHO: World Health Organization; JAK: Janus kinase; CALR: Calreticulin; bp: base pair; MPL: Myelo Proliferative Leukemia virus oncogene; TPO: Thrombo Protein; RARS-T: Refractory Anemia with Ring Sideroblasts associated with marked Thrombocytosis; PMF: Primary Myelo Fibrosis; IPSET: The International Prognostic Score for Essential Thrombocythemia; WBC: White Blood Cell; LMWH: Low-Molecular Weight Heparin; SVT: Splanchnic Vein Thrombosis Intro
Read more

A Young Woman with Coomb's Positive Severe Haemolytic Anaemia and Hodgkin Lymphoma that Responded Completely to Rituximab: A Case Report

Image
  Cancer Therapy & Oncology- Juniper Publishers                                                      Abstract Introduction Lymphoma has been historically divided into a Hodgkin and Non-Hodgkin variety. There are reported cases of Hemolytic Anemia in Non- Hodgkin Lymphoma but Hodgkin Lymphoma very rarely also present with Hemolytic Anemias. Case presentation A 27-year-old African woman presented with chronic fatigue, dyspnoea, jaundice and Splenomegalie. Her blood work revealed severe anaemia (haemoglobin, 4.9 g/dl) with biochemical evidence of haemolysis. A direct Coomb's test was reported positive. A biopsy of the lymph nodes in the neck confirmed Hodgkin Lymphoma. Initial therapy consisted of intravenous methyl prednisolone and switched over to Oral Prednisolone. However, the patient came back with raised sugar levels and there was no clinically response. The patient continued to have lower hemoglobin levels and was transfused blood repeatedly. She was started on chemotherapy
Read more